Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | VB10.16 |
Synonyms | |
Therapy Description |
VB10.16 is a DNA vaccine comprised of inactivated HPV16 E6 and E7 proteins attached to the chemokine macrophage inflammatory protein-1 alpha (MIP-1alpha), which may lead to activation of immune response and tumor cell lysis (Annals of Oncology 31 (2020): S645-S646; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VB10.16 | DNA Vaccine VB10.16 | VB10.16 is a DNA vaccine comprised of inactivated HPV16 E6 and E7 proteins attached to the chemokine macrophage inflammatory protein-1 alpha (MIP-1alpha), which may lead to activation of immune response and tumor cell lysis (Annals of Oncology 31 (2020): S645-S646; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06099418 | Phase II | VB10.16 Atezolizumab + VB10.16 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | Withdrawn | 0 |